Newsroom | 3730 results

COLTON, Calif.--(BUSINESS WIRE)--California University of Science and Medicine (CUSM) today announced that the 2025 MD graduating class received residency placements as part of the national Match Day event. Sixty-six percent of CUSM Doctor of Medicine (MD) grads will perform their residency in southern California; twenty-eight percent will remain in the Inland Empire. Match Day is the culmination of the National Resident Matching Program, in which all graduating MDs seek residency positions in...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Today, Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, announced manufacturing, research and development, and technology investments of more than $55 billion in the United States over the next four years. This represents a 25% increase in investment compared to the previous four years and builds upon the Company’s already elevated U.S. investment levels resulting from the passage of the 2017...

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Enigma Biomedical USA, Inc. (EB USA) today announced that it has selected two (2) four-repeat tau (4R Tau) protein PET imaging biomarkers to advance into Phase 1 (Ph1) studies. Previously, EB USA executed an Exclusive License and Option Agreement (License) with AbbVie for the development and potential commercialization of AbbVie’s next-generation F18 PET imaging biomarkers to assess the presence of 4R Tau in subjects with suspected neurodegenerative disease. T...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the full-year ended December 31, 2024, and highlighted recent progress across its pipeline of clinical-stage product candidates. “In 2024 we continued to advance our mission to change the way medicines are developed for neuropsychiatric conditio...

MANHASSET, N.Y.--(BUSINESS WIRE)--The Feinstein Institutes for Medical Research has been awarded $3 million from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), in collaboration with imec, to pioneer a novel approach to vagus nerve stimulation (VNS). This research aims to develop more precise, safe and effective methods for stimulating specific fibers inside the vagus nerve, potentially transforming treatments for a range of...

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2024 on March 31, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the...

MANHASSET, N.Y.--(BUSINESS WIRE)--The sixth annual Bioelectronic Medicine Summit, hosted by Northwell Health’s Feinstein Institutes for Medical Research, brought together leading scientists, engineers, clinicians and innovators in the fields of translational medicine, neuromodulation and bioengineering. The Summit was co-chaired by Stavros Zanos, MD, PhD, associate professor in the Institute of Bioelectronic Medicine, and Hubert Lim, PhD, professor at the University of Minnesota, and focused on...

CHICAGO--(BUSINESS WIRE)--The Periodic Paralysis Association is excited to announce that March 23rd, 2025 is the inaugural World Periodic Paralysis Day....

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced initial Phase 1 data in an oral presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas, Texas. “We are very pleased by these early clinical data reinforcing the translation of SAT-3247’s prec...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada from April 3 to 5, 2025. The Company’s poster presentations will explore the age of onset of social anxiety diso...